Glaxo Pauses RSV Trial in Pregnant Women After Safety Review
- Vaccine study in older adults isn’t affected, drugmaker says
- Decision is a setback for Glaxo in hunt for RSV shot
This article is for subscribers only.
GlaxoSmithKline Plc paused a late-stage trial evaluating an experimental vaccine against a respiratory virus called RSV in pregnant women following a safety recommendation from an independent committee.
The move is a setback for Glaxo as the U.K. drugmaker targets a virus that can be especially serious for infants and older adults and pursues a potential multibillion-dollar market opportunity along with competitors. A vaccine for respiratory syncytial virus has eluded scientists for decades.